Publications by authors named "J P Ungerer"
Why severe injury to the central nervous system (CNS) triggers the development of large neurogenic heterotopic ossifications (NHOs) within periarticular muscles remains unknown. We report that spinal cord injury (SCI) triggers a rapid corticosterone spike in mice, which is causal for NHO development because treatments with corticosterone or the synthetic glucocorticoid (GC) receptor (GR) agonist dexamethasone are sufficient to trigger heterotopic ossification and upregulate the expression of osteoinductive and osteogenic differentiation genes in injured muscles even without SCI. The central role for GR signaling in causing NHO is further demonstrated in mice deleted for the GR gene (Nr3c1), which no longer develop NHO after SCI.
View Article and Find Full Text PDFArticle Synopsis
- Guidelines suggest giving kids with bacterial meningitis a medicine called ceftriaxone in certain doses.
- Researchers studied how well this medicine enters the brain's protective fluid in kids and found that the once-daily method works better than the twice-daily method for some bacteria.
- They learned that while the once-a-day dose is better, neither dose worked well enough for treating all kinds of meningitis.
Background: Ivermectin, an effective treatment for scabies, is not licensed for children weighing <15 kg. Pharmacokinetic modelling has shown a 3 mg dose in young children (2-4 years, weighing 10-14 kg) achieves comparable drug exposure to a 200 μg/kg dose in children aged ≥5 years. This trial evaluated a 3 mg dose in young children.
View Article and Find Full Text PDFGatemon qubits are the electrically tunable cousins of superconducting transmon qubits. In this work, we demonstrate the full coherent control of a gatemon qubit based on hole carriers in a Ge/Si core/shell nanowire, with the longest coherence times in group IV material gatemons to date. The key to these results is a high-quality Josephson junction obtained using a straightforward and reproducible annealing technique.
View Article and Find Full Text PDFArticle Synopsis
- Protein biosensors have great potential, but their development usually involves a trial-and-error method, prompting the need for modular designs for better target recognition.
- A new workflow was created that uses advanced selection techniques to produce stable binding domains for specific targets, integrated into a unique biosensor architecture.
- Testing on liver toxicity markers showed the method consistently yielded over 10 different binders in a week, though binder affinity did not necessarily correlate with biosensor performance, highlighting the importance of design interactions.